Daniel G. Dauner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel G. Dauner has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Eleazar Leal
Department of Computer Science, Swenson College of Science and Engineering, University of Minnesota, Duluth, Minnesota, USA
2 shared publications- Joel F. Farley
Department of Pharmaceutical Care & Health Systems College of Pharmacy, University of Minnesota Minneapolis Minnesota USA
2 shared publications - Kim Nichols Dauner
Department of Economics and Health Care Management, Labovitz School of Business and Economics, University of Minnesota Duluth, Duluth, MN, United States
2 shared publications Rui Zhang
Division of Computational Health Sciences, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
2 shared publicationsTerrence J. Adam
Department of Pharmaceutical Care and Health Systems, College of Pharmacy, Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA
2 shared publications- Annalisa L.H. Peterson
Department of Economics and Health Care Management, Labovitz School of Business and Economics, University of Minnesota Duluth, USA
1 shared publication
Latest Publications
- 7 March 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (7) , 589-597
Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system
Many signal detection algorithms give the same weight to information from all products and patients, which may result in signals being masked or false positives being flagged as potential signals. ...
- 7 March 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (7) , 589-597
Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system
Many signal detection algorithms give the same weight to information from all products and patients, which may result in signals being masked or false positives being flagged as potential signals. ...
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 14
Evaluation of four machine learning models for signal detection
Background: Logistic regression-based signal detection algorithms have benefits over disproportionality analysis due to their ability to handle potential confounders and masking factors. Feature exploration and developing alternative machine learning algorithms can further strengthen signal detection. Objectives: Our objective was to compare the signal detection performance of logistic regression, gradient-boosted trees, random forest and support vector machine models utilizing Food and Drug Administration adverse event reporting system data. Design: Cross-sectional study. Methods: The quarterly data extract files from 1 October 2017 through 31 December 2020 were downloaded. Due to an imbalanced outcome, two training sets were used: one stratified on the outcome variable and another using Synthetic Minority Oversampling Technique (SMOTE). A crude model and a model with tuned hyperparameters were developed for each algorithm. Model performance was compared against a reference set using accuracy, precision, F1 score, recall, the receiver operating characteristic area under the curve (ROCAUC), and the precision-recall curve area under the curve (PRCAUC). Results: Models trained on the balanced training set had higher accuracy, F1 score and recall compared to models trained on the SMOTE training set. When using the balanced training set, logistic regression, gradient-boosted trees, random forest and support vector machine models obtained similar performance evaluation metrics. The gradient-boosted trees hyperparameter tuned model had the highest ROCAUC (0.646) and the random forest crude model had the highest PRCAUC (0.839) when using the balanced training set. Conclusion: All models trained on the balanced training set performed similarly. Logistic regression models had higher accuracy, precision and recall. Logistic regression, random forest and gradient-boosted trees hyperparameter tuned models had a PRCAUC ⩾ 0.8. All models had an ROCAUC ⩾ 0.5. Including both disproportionality analysis results and additional case report information in models resulted in higher performance evaluation metrics than disproportionality analysis alone.
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 14
Open AccessEvaluation of four machine learning models for signal detection
Background: Logistic regression-based signal detection algorithms have benefits over disproportionality analysis due to their ability to handle potential confounders and masking factors. Feature exploration and developing alternative machine learning algorithms can further strengthen signal detection. Objectives: Our objective was to compare the signal detection performance of logistic regression, gradient-boosted trees, random forest and support vector machine models utilizing Food and Drug Administration adverse event reporting system data. Design: Cross-sectional study. Methods: The quarterly data extract files from 1 October 2017 through 31 December 2020 were downloaded. Due to an imbalanced outcome, two training sets were used: one stratified on the outcome variable and another using Synthetic Minority Oversampling Technique (SMOTE). A crude model and a model with tuned hyperparameters were developed for each algorithm. Model performance was compared against a reference set using accuracy, precision, F1 score, recall, the receiver operating characteristic area under the curve (ROCAUC), and the precision-recall curve area under the curve (PRCAUC). Results: Models trained on the balanced training set had higher accuracy, F1 score and recall compared to models trained on the SMOTE training set. When using the balanced training set, logistic regression, gradient-boosted trees, random forest and support vector machine models obtained similar performance evaluation metrics. The gradient-boosted trees hyperparameter tuned model had the highest ROCAUC (0.646) and the random forest crude model had the highest PRCAUC (0.839) when using the balanced training set. Conclusion: All models trained on the balanced training set performed similarly. Logistic regression models had higher accuracy, precision and recall. Logistic regression, random forest and gradient-boosted trees hyperparameter tuned models had a PRCAUC ⩾ 0.8. All models had an ROCAUC ⩾ 0.5. Including both disproportionality analysis results and additional case report information in models resulted in higher performance evaluation metrics than disproportionality analysis alone.
- 1 May 2021
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 61 (3) , 293-298
Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic
- 1 May 2021
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 61 (3) , 293-298
Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic
- 26 March 2021
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 20 (4) , 475-480
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy
Background: The SUSTAIN-6 trial showed significantly higher rates of retinopathy complications in the semaglutide group compared to placebo. Observational studies have not consistently corroborated this finding, raising questions about the appropriateness of composite variables and whether the relationship exists across the entire drug class or is limited to individual glucagon-like peptide 1 agonists (GLP-1RAs). The study objective was to evaluate the difference between using individual and composite terms to assess associations between GLP-1RAs and diabetic retinopathy events. Research Design and Methods: Reports from the US Food and Drug Administration Adverse Event Reporting System were utilized to examine relationships between GLP-1RAs and diabetic retinopathy events. A disproportionality analysis was conducted using the proportional reporting ratio. Results: Four GLP-1RAs demonstrated signals for diabetic retinopathy events. The GLP-1RA drug class had four diabetic retinopathy signals. Only semaglutide had a signal for the composite diabetic retinopathy outcome. The GLP-1RA drug class and the composite diabetic retinopathy outcome did not meet the PRR signal thresholds. Conclusions: The use of drug class level and composite outcome variables may mask diabetic retinopathy signals in comparison to individual drug assessments. Our results support the SUSTAIN-6 trial findings and suggest an association between four GLP-1RAs and diabetic retinopathy events.
- 26 March 2021
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 20 (4) , 475-480
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy
Background: The SUSTAIN-6 trial showed significantly higher rates of retinopathy complications in the semaglutide group compared to placebo. Observational studies have not consistently corroborated this finding, raising questions about the appropriateness of composite variables and whether the relationship exists across the entire drug class or is limited to individual glucagon-like peptide 1 agonists (GLP-1RAs). The study objective was to evaluate the difference between using individual and composite terms to assess associations between GLP-1RAs and diabetic retinopathy events. Research Design and Methods: Reports from the US Food and Drug Administration Adverse Event Reporting System were utilized to examine relationships between GLP-1RAs and diabetic retinopathy events. A disproportionality analysis was conducted using the proportional reporting ratio. Results: Four GLP-1RAs demonstrated signals for diabetic retinopathy events. The GLP-1RA drug class had four diabetic retinopathy signals. Only semaglutide had a signal for the composite diabetic retinopathy outcome. The GLP-1RA drug class and the composite diabetic retinopathy outcome did not meet the PRR signal thresholds. Conclusions: The use of drug class level and composite outcome variables may mask diabetic retinopathy signals in comparison to individual drug assessments. Our results support the SUSTAIN-6 trial findings and suggest an association between four GLP-1RAs and diabetic retinopathy events.
- 1 June 2020
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (6) , 844-847
FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients
- 1 June 2020
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 16 (6) , 844-847
FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients